Proteome Sciences uses ProteoSHOP®, its high output proteomics toolkit, to facilitate the discovery of differentially expressed protein biomarkers for novel diagnostic, prognostic and therapeutic applications which are commercialised, through out-licenses, to diagnostic and pharmaceutical companies.

Neurological diseases

Conditions being studied include brain damage, stroke, prion diseases including vCJD, CJD and BSE, Alzheimer’s, depression and Parkinson's disease.

Cardiovascular diseases

The main areas addressed include ischaemia and dilated cardiomyopathy (DCM).

Solid organ transplant rejection

Proteome Sciences has developed a non-invasive method for detecting acute and chronic rejection following heart transplantation. The programme also addresses rejection markers for kidney, liver and lung transplantation.

Diabetes & obesity

Proteomic methods are being used to identify peptides, correlating with predisposition, onset and progression of obesity and diabetes, as potential biomarkers and therapeutic targets and for protein expression profiling after drug treatment.

Oncology

Tumour types under investigation include oesophageal, lung, colon, prostate, breast, neuroblastoma, and glioma.

COMMERCIALISATION

Proteome Sciences has an impressive portfolio of patents, granted and pending, on proteins found to be altered in some of the most common and serious diseases in these therapeutic areas. These discoveries will form the basis of new diagnostic and therapeutic products to be commercialised by strategic alliance and corporate partners.

Other areas of specialist research:

• RNA therapy
• Gene therapy
• Molecular imaging
• Exon tagging
• Quality control

are carried out by associate companies, Intronn Inc. and Veri-Q Inc.